On the public citation graph
Virus-specific T-cell banks for 'off the shelf' adoptive therapy of refractory infections
0 signed · 240 inferred · view as graph
Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.
Is this your work? Sign in with ORCID and put your name on the
claims that are yours.
Reference health. See whether every reference in this work resolves to a
known work and none has been retracted — and get a dated CiteStamped
badge you can embed.
What this work says
Outgoing claims: the papers this work cites, builds on, or argues with.
inferredcites →https://doi.org/10.1016/j.bbmt.2007.02.004openalex-snapshot
Ex Vivo Expansion and Prophylactic Infusion of CMV-pp65 Peptide-Specific Cytotoxic T-Lymphocytes following Allogeneic Hematopoietic Stem Cell Transplantation
inferredcites →https://doi.org/10.1016/j.bbmt.2012.11.072openalex-snapshot
Epitopes of CMVpp65 Co-Presented by Multiple Allelic Variants of HLA Class-I Antigens: Implications for Adoptive Immunotherapy for CMV Using Third Party Donor – Derived CMV Specific CTLs
inferredcites →https://doi.org/10.1016/j.bbmt.2013.07.015openalex-snapshot
CMV-, EBV- and ADV-Specific T Cell Immunity: Screening and Monitoring of Potential Third-Party Donors to Improve Post-Transplantation Outcome
inferredcites →https://doi.org/10.1016/j.bbmt.2015.05.015openalex-snapshot
Immunotherapy with Donor T Cells Sensitized with Overlapping Pentadecapeptides for Treatment of Persistent Cytomegalovirus Infection or Viremia
inferredcites →https://doi.org/10.1016/j.beha.2011.06.001openalex-snapshot
Novel strategies for adoptive therapy following HLA disparate transplants
inferredcites →https://doi.org/10.1016/j.semcancer.2008.10.008openalex-snapshot
Epstein-Barr virus evasion of CD8+ and CD4+ T cell immunity via concerted actions of multiple gene products
inferredcites →https://doi.org/10.1016/s0140-6736(02)09672-1openalex-snapshot
Treatment of Epstein-Barr-virus-positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells
inferredcites →https://doi.org/10.1016/s0140-6736(03)14634-xopenalex-snapshot
Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines
inferredcites →https://doi.org/10.1016/s0198-8859(03)00028-4openalex-snapshot
Relative dominance of HLA-B*07 restricted CD8+ T-Lymphocyte immune responses to human cytomegalovirus pp65 in persons sharing HLA-A*02 and HLA-B*07 alleles
inferredcites →https://doi.org/10.1016/s0966-3274(96)80038-4openalex-snapshot
CD45RA+ and CD45RO+ T cells differ in susceptibility to cyclosporin A mediated inhibition of interleukin-2 production
inferredcites →https://doi.org/10.1038/375685a0openalex-snapshot
Inhibition of antigen processing by the internal repeat region of the Epstein–Barr virus nuclear antigen-1
inferredcites →https://doi.org/10.1038/bmt.2010.221openalex-snapshot
Polyomavirus JC-targeted T-cell therapy for progressive multiple leukoencephalopathy in a hematopoietic cell transplantation recipient
inferredcites →https://doi.org/10.1038/mt.2013.151openalex-snapshot
Safety and clinical efficacy of rapidly-generated trivirus-directed T cells as treatment for adenovirus, EBV, and CMV infections after allogeneic hematopoietic stem cell transplant
inferredcites →https://doi.org/10.1038/ni.2097openalex-snapshot
Human cytomegalovirus microRNA miR-US4-1 inhibits CD8+ T cell responses by targeting the aminopeptidase ERAP1
inferredcites →https://doi.org/10.1038/nm.1882openalex-snapshot
Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma
inferredcites →https://doi.org/10.1038/nm1475openalex-snapshot
Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals
inferredcites →https://doi.org/10.1038/nrclinonc.2012.111openalex-snapshot
T-cell therapy in the treatment of post-transplant lymphoproliferative disease
inferredcites →https://doi.org/10.1038/sj.bmt.1705699openalex-snapshot
Risk factors associated with late cytomegalovirus reactivation after allogeneic stem cell transplantation for hematological malignancies
inferredcites →https://doi.org/10.1038/sj.gt.3302316openalex-snapshot
Adenovirus hexon T-cell epitope is recognized by most adults and is restricted by HLA DP4, the most common class II allele
inferredcites →https://doi.org/10.1056/nejm199404283301703openalex-snapshot
Infusions of Donor Leukocytes to Treat Epstein-Barr Virus-Associated Lymphoproliferative Disorders after Allogeneic Bone Marrow Transplantation
inferredcites →https://doi.org/10.1056/nejm199510193331603openalex-snapshot
Reconstitution of Cellular Immunity against Cytomegalovirus in Recipients of Allogeneic Bone Marrow by Transfer of T-Cell Clones from the Donor
inferredcites →https://doi.org/10.1056/nejmoa041276openalex-snapshot
Outcomes after Transplantation of Cord Blood or Bone Marrow from Unrelated Donors in Adults with Leukemia
inferredcites →https://doi.org/10.1073/pnas.93.20.10990openalex-snapshot
Human cytomegalovirus inhibits antigen presentation by a sequential multistep process.
inferredcites →https://doi.org/10.1080/10428190600881157openalex-snapshot
Adenovirus infection after allogeneic stem cell transplantation
inferredcites →https://doi.org/10.1084/jem.20040613openalex-snapshot
Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA–peptide tetramers
inferredcites →https://doi.org/10.1093/cid/ciq042openalex-snapshot
Directly Selected Cytomegalovirus-Reactive Donor T Cells Confer Rapid and Safe Systemic Reconstitution of Virus-Specific Immunity Following Stem Cell Transplantation
inferredcites →https://doi.org/10.1093/cid/cis625openalex-snapshot
Rapid Salvage Treatment With Virus-Specific T Cells for Therapy-Resistant Disease
inferredcites →https://doi.org/10.1097/cji.0b013e31824300a2openalex-snapshot
Adoptive Immunotherapy With CMV-specific Cytotoxic T Lymphocytes for Stem Cell Transplant Patients With Refractory CMV Infections
inferredcites →https://doi.org/10.1097/cji.0b013e318270e112openalex-snapshot
Induction of Thelper1-driven Antiviral T-cell Lines for Adoptive Immunotherapy Is Determined by Differential Expression of IFN-γ and T-cell Activation Markers
inferredcites →https://doi.org/10.1097/cji.0b013e318279652eopenalex-snapshot
Human Papillomavirus Type 16 E6/E7-specific Cytotoxic T Lymphocytes for Adoptive Immunotherapy of HPV-associated Malignancies
inferredcites →https://doi.org/10.1097/cji.0b013e31827b87ccopenalex-snapshot
HCMV-specific T-cell Therapy
inferredcites →https://doi.org/10.1097/cji.0b013e3182a8029eopenalex-snapshot
HLA-Peptide Multimer Selection of Adenovirus-specific T Cells For Adoptive T-Cell Therapy
inferredcites →https://doi.org/10.1097/tp.0b013e31823328c0openalex-snapshot
BK Virus-Specific T Cells for Use in Cellular Therapy Show Specificity to Multiple Antigens and Polyfunctional Cytokine Responses
inferredcites →https://doi.org/10.1111/bjh.12251openalex-snapshot
Interferon‐γ capture T cell therapy for persistent A denoviraemia following allogeneic haematopoietic stem cell transplantation
inferredcites →https://doi.org/10.1111/j.1365-2141.2006.06108.xopenalex-snapshot
Safe adoptive transfer of virus‐specific T‐cell immunity for the treatment of systemic adenovirus infection after allogeneic stem cell transplantation
inferredcites →https://doi.org/10.1111/j.1537-2995.2010.02940.xopenalex-snapshot
Adoptive transfer and selective reconstitution of streptamer‐selected cytomegalovirus‐specific CD8+ T cells leads to virus clearance in patients after allogeneic peripheral blood stem cell transplantation
inferredcites →https://doi.org/10.1111/j.1600-6143.2006.01650.xopenalex-snapshot
Epstein-Barr Virus: Evasive Maneuvers in the Development of PTLD
inferredcites →https://doi.org/10.1126/science.1352912openalex-snapshot
Restoration of Viral Immunity in Immunodeficient Humans by the Adoptive Transfer of T Cell Clones
inferredcites →https://doi.org/10.1126/scitranslmed.3008825openalex-snapshot
Activity of Broad-Spectrum T Cells as Treatment for AdV, EBV, CMV, BKV, and HHV6 Infections after HSCT
inferredcites →https://doi.org/10.1158/1538-7445.am2015-ct107openalex-snapshot
Abstract CT107: Epstein-Barr virus-specific cytotoxic T lymphocytes for treatment of rituximab-refractory Epstein-Barr virus-associated lymphoproliferative disorder
inferredcites →https://doi.org/10.1172/jci32103openalex-snapshot
Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates
inferredcites →https://doi.org/10.1182/blood-2003-05-1433openalex-snapshot
Generation of CMV-specific T lymphocytes using protein-spanning pools of pp65-derived overlapping pentadecapeptides for adoptive immunotherapy
inferredcites →https://doi.org/10.1182/blood-2005-10-006536openalex-snapshot
In vitro priming and expansion of cytomegalovirus-specific Th1 and Tc1 T cells from naive cord blood lymphocytes
inferredcites →https://doi.org/10.1182/blood-2006-12-063008openalex-snapshot
Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial
inferredcites →https://doi.org/10.1182/blood-2009-03-213256openalex-snapshot
Functionally active virus-specific T cells that target CMV, adenovirus, and EBV can be expanded from naive T-cell populations in cord blood and will target a range of viral epitopes
inferredcites →https://doi.org/10.1182/blood-2009-08-239186openalex-snapshot
Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients
inferredcites →https://doi.org/10.1182/blood-2010-01-262089openalex-snapshot
Adoptive transfer of pp65-specific T cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell transplantation
inferredcites →https://doi.org/10.1182/blood-2010-04-281873openalex-snapshot
Successful treatment of EBV-associated posttransplantation lymphoma after cord blood transplantation using third-party EBV-specific cytotoxic T lymphocytes
inferredcites →https://doi.org/10.1182/blood-2011-05-354449openalex-snapshot
Antitumor activity and long-term fate of chimeric antigen receptor–positive T cells in patients with neuroblastoma
inferredcites →https://doi.org/10.1182/blood-2011-08-371971openalex-snapshot
Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation
inferredcites →https://doi.org/10.1182/blood-2012-05-430413openalex-snapshot
Immunotherapeutic strategies to prevent and treat human herpesvirus 6 reactivation after allogeneic stem cell transplantation
inferredcites →https://doi.org/10.1182/blood-2012-08-448977openalex-snapshot
Donor-derived CMV-specific T cells reduce the requirement for CMV-directed pharmacotherapy after allogeneic stem cell transplantation
inferredcites →https://doi.org/10.1182/blood-2012-09-453720openalex-snapshot
Cytomegalovirus-specific T cells are primed early after cord blood transplant but fail to control virus in vivo
inferredcites →https://doi.org/10.1182/blood-2013-02-486324openalex-snapshot
Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation
inferredcites →https://doi.org/10.1182/blood-2013-04-498956openalex-snapshot
JAK2V617F expression in mice amplifies early hematopoietic cells and gives them a competitive advantage that is hampered by IFNα
inferredcites →https://doi.org/10.1182/blood-2014-03-562538openalex-snapshot
Paraneoplastic thrombocytosis: the secrets of tumor self-promotion
inferredcites →https://doi.org/10.1182/blood-2014-05-571646openalex-snapshot
Triple jeopardy for Hodgkin lymphoma survivors?
inferredcites →https://doi.org/10.1182/blood.v122.21.2021.2021openalex-snapshot
Generation and Characterization Of a Third Party GMP Grade Bank Of CMV Specific T-Cells For Adoptive Immunotherapy Of CMV Infections In Recipients Of HSCT From Cord Blood Or Seronegative Donors
inferredcites →https://doi.org/10.1182/blood.v122.21.sci-39.sci-39openalex-snapshot
Selecting T-Cell Subsets for Adoptive T-Cell Therapy to Optimize Potency and Persistence
inferredcites →https://doi.org/10.1182/blood.v124.21.184.184openalex-snapshot
Third Party Donor Derived CMV Specific T Cells for the Treatment of Refractory CMV Viremia and Disease after Hematopoietic Stem Cell Transplant
inferredcites →https://doi.org/10.1182/blood.v124.21.309.309openalex-snapshot
Banked, GMP Grade Third Party T-Cell Lines Specific for CMVpp65 Epitopes Presented By Certain Prevalent HLA Alleles More Consistently Clear CMV Infections in a Genetically Heterogeneous Population of HSCT Recipients
inferredcites →https://doi.org/10.1182/blood.v87.6.2594.bloodjournal8762594openalex-snapshot
The development of cellular immunity to Epstein-Barr virus after allogeneic bone marrow transplantation
inferredcites →https://doi.org/10.1182/blood.v92.5.1549openalex-snapshot
Infusion of Cytotoxic T Cells for the Prevention and Treatment of Epstein-Barr Virus–Induced Lymphoma in Allogeneic Transplant Recipients
inferredcites →https://doi.org/10.1182/blood.v97.4.835openalex-snapshot
An Epstein-Barr virus deletion mutant associated with fatal lymphoproliferative disease unresponsive to therapy with virus-specific CTLs
inferredcites →https://doi.org/10.1182/blood.v99.11.3916openalex-snapshot
Infusion of cytomegalovirus (CMV)–specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy
inferredcites →https://doi.org/10.1371/journal.pone.0003634openalex-snapshot
Levels of CMV Specific CD4 T Cells Are Dynamic and Correlate with CMV Viremia after Allogeneic Stem Cell Transplantation
inferredcites →https://doi.org/10.1517/14712598.8.9.1265openalex-snapshot
Adoptive cell therapy against EBV-related malignancies: a survey of clinical results
inferredcites →https://doi.org/10.3109/14653249.2011.636963openalex-snapshot
Production of good manufacturing practice-grade cytotoxic T lymphocytes specific for Epstein–Barr virus, cytomegalovirus and adenovirus to prevent or treat viral infections post-allogeneic hematopoietic stem cell transplant
inferredcites →https://doi.org/10.3389/fimmu.2012.00410openalex-snapshot
Adoptive T-cell immunotherapy from third-party donors: characterization of donors and set up of a T-cell donor registry
inferredcites →https://doi.org/10.4049/jimmunol.0804178openalex-snapshot
A Panel of Artificial APCs Expressing Prevalent HLA Alleles Permits Generation of Cytotoxic T Cells Specific for Both Dominant and Subdominant Viral Epitopes for Adoptive Therapy
inferredcites →https://doi.org/10.4049/jimmunol.1302281openalex-snapshot
CD8 T Cell–Evasive Functions of Human Cytomegalovirus Display Pervasive MHC Allele Specificity, Complementarity, and Cooperativity
What points at this work
Incoming claims: where this work appears in other papers’ reference lists and arguments.
inferred← citeshttps://doi.org/10.2139/ssrn.3904656openalex-extracted
Comparison of Transplant Donor- and Third-Party Donor-Derived CMV-Specific T Cells for CMV Infection After Allogenic Stem Cell Transplantation
inferred← citeshttps://doi.org/10.1002/acg2.101openalex-snapshot
Rapid production of clinical‐grade SARS‐CoV‐2 specific T cells
inferred← citeshttps://doi.org/10.1002/acg2.86openalex-snapshot
Toward “off‐the‐shelf” allogeneic CAR T cells
inferred← citeshttps://doi.org/10.1002/ajh.26535openalex-snapshot
Adoptive therapy with cytomegalovirus ‐specific T cells for cytomegalovirus infection after haploidentical stem cell transplantation and factors affecting efficacy
inferred← citeshttps://doi.org/10.1007/5584_2020_606openalex-snapshot
Potential of Chimeric Antigen Receptor T-Cells in Cancer Therapy
inferred← citeshttps://doi.org/10.1007/978-3-030-00362-3_13openalex-snapshot
Aggressive Lymphoma in Children and Adolescents
inferred← citeshttps://doi.org/10.1007/978-3-030-01322-6_8openalex-snapshot
Hematopoietic Stem Cell Transplant and Cellular Therapy
inferred← citeshttps://doi.org/10.1007/978-3-030-11769-6_26openalex-snapshot
Novel Therapies in Paediatric NHL
inferred← citeshttps://doi.org/10.1007/978-3-030-53626-8_55openalex-snapshot
T-Cell Therapeutics: Donor Lymphocyte Infusion, Cytotoxic T-Lymphocyte Infusion, and Other Non-CAR T-Cell Therapies
inferred← citeshttps://doi.org/10.1007/978-3-031-28797-8_10openalex-snapshot
Cytomegalovirus Diseases in Hematopoietic Cell Transplant Recipients
inferred← citeshttps://doi.org/10.1007/978-3-031-57369-9_11openalex-snapshot
Community-Acquired Respiratory Infections in HCT and Immunosuppressed Patients
inferred← citeshttps://doi.org/10.1007/978-3-662-46764-0_155-1openalex-snapshot
Therapie von Infektionen bei Tumorpatienten
inferred← citeshttps://doi.org/10.1007/978-981-15-3350-1_3openalex-snapshot
Genome Engineering Tools in Immunotherapy
inferred← citeshttps://doi.org/10.1007/s00259-024-06814-7openalex-snapshot
89Zr-immunoPET-guided selection of a CD33xIL15 fusion protein optimized for antitumor immune cell activation and in vivo tumour retention in acute myeloid leukaemia
inferred← citeshttps://doi.org/10.1007/s00262-018-2118-zopenalex-snapshot
Epstein–Barr virus strain heterogeneity impairs human T-cell immunity
inferred← citeshttps://doi.org/10.1007/s00262-025-04278-8openalex-snapshot
Unleashing CAR-T potential in solid tumors: overcoming intrinsic and extrinsic hurdles to improve therapy
inferred← citeshttps://doi.org/10.1007/s11357-023-00858-7openalex-snapshot
Effective virus-specific T-cell therapy for high-risk SARS-CoV-2 infections in hematopoietic stem cell transplant recipients: initial case studies and literature review
inferred← citeshttps://doi.org/10.1007/s11864-021-00920-6openalex-snapshot
Allogeneic Chimeric Antigen Receptor Therapy in Lymphoma
inferred← citeshttps://doi.org/10.1007/s11882-017-0669-2openalex-snapshot
Adoptive T Cell Immunotherapy for Patients with Primary Immunodeficiency Disorders
inferred← citeshttps://doi.org/10.1007/s11908-019-0699-0openalex-snapshot
CMV Prevention and Treatment in Transplantation: What’s New in 2019
inferred← citeshttps://doi.org/10.1016/b978-0-323-63671-1.00028-8openalex-snapshot
Post-transplant Lymphoproliferative Disease
inferred← citeshttps://doi.org/10.1016/b978-0-7020-6896-6.00037-5openalex-snapshot
Infections in the Immunocompromised Host
inferred← citeshttps://doi.org/10.1016/j.antiviral.2018.03.001openalex-snapshot
USC-087 protects Syrian hamsters against lethal challenge with human species C adenoviruses
inferred← citeshttps://doi.org/10.1016/j.bbmt.2017.10.004openalex-snapshot
Virus-Specific T Cells: Broadening Applicability
inferred← citeshttps://doi.org/10.1016/j.bbmt.2017.12.787openalex-snapshot
Reprint of: Virus-Specific T Cells: Broadening Applicability
inferred← citeshttps://doi.org/10.1016/j.bbmt.2018.10.010openalex-snapshot
Build a Bank: Off-the-Shelf Virus-Specific T Cells
inferred← citeshttps://doi.org/10.1016/j.bbmt.2019.10.003openalex-snapshot
Ex Vivo T Cell-Depleted Hematopoietic Stem Cell Transplantation for Adult Patients with Acute Myelogenous Leukemia in First and Second Remission: Long-Term Disease-Free Survival with a Significantly Reduced Risk of Graft-versus-Host Disease
inferred← citeshttps://doi.org/10.1016/j.biopha.2023.115888openalex-snapshot
The paths and challenges of “off-the-shelf” CAR-T cell therapy: An overview of clinical trials
inferred← citeshttps://doi.org/10.1016/j.blre.2018.11.001openalex-snapshot
Allogeneic hematopoietic cell transplantation; the current renaissance
inferred← citeshttps://doi.org/10.1016/j.blre.2021.100807openalex-snapshot
Clinical features and treatment strategies for post-transplant and iatrogenic immunodeficiency-associated lymphoproliferative disorders
inferred← citeshttps://doi.org/10.1016/j.bulcan.2021.01.025openalex-snapshot
Développement des CAR-T allogéniques
inferred← citeshttps://doi.org/10.1016/j.cell.2020.03.001openalex-snapshot
The Emerging Landscape of Immune Cell Therapies
inferred← citeshttps://doi.org/10.1016/j.cellimm.2021.104398openalex-snapshot
An outlook on antigen-specific adoptive immunotherapy for viral infections with a focus on COVID-19
inferred← citeshttps://doi.org/10.1016/j.celrep.2021.109432openalex-snapshot
Generation of Glucocorticoid Resistant SARS-CoV-2 T-Cells for Adoptive Cell Therapy
inferred← citeshttps://doi.org/10.1016/j.coi.2023.102305openalex-snapshot
αβ and γδ T-cell responses to Epstein-Barr Virus: insights in immunocompetence, immune failure and therapeutic augmentation in transplant patients
inferred← citeshttps://doi.org/10.1016/j.coviro.2018.08.010openalex-snapshot
Immune-based therapeutic approaches to virus-associated cancers
inferred← citeshttps://doi.org/10.1016/j.isci.2020.100998openalex-snapshot
Cytotoxic T Lymphocytes Regenerated from iPS Cells Have Therapeutic Efficacy in a Patient-Derived Xenograft Solid Tumor Model
inferred← citeshttps://doi.org/10.1016/j.jaip.2018.10.049openalex-snapshot
Virus-Specific T Cells: Current and Future Use in Primary Immunodeficiency Disorders
inferred← citeshttps://doi.org/10.1016/j.jcyt.2017.08.010openalex-snapshot
Epstein-Barr virus lymphoproliferative disease after solid organ transplantation
inferred← citeshttps://doi.org/10.1016/j.jcyt.2017.12.002openalex-snapshot
The doubling potential of T lymphocytes allows clinical-grade production of a bank of genetically modified monoclonal T-cell populations
inferred← citeshttps://doi.org/10.1016/j.jcyt.2021.03.001openalex-snapshot
Identification of novel HLA-restricted preferentially expressed antigen in melanoma peptides to facilitate off-the-shelf tumor-associated antigen-specific T-cell therapies
inferred← citeshttps://doi.org/10.1016/j.jcyt.2022.05.010openalex-snapshot
Viral infection in hematopoietic stem cell transplantation: an International Society for Cell & Gene Therapy Stem Cell Engineering Committee review on the role of cellular therapy in prevention and treatment
inferred← citeshttps://doi.org/10.1016/j.jtct.2021.09.010openalex-snapshot
American Society for Transplantation and Cellular Therapy Series: #4 - Cytomegalovirus treatment and management of resistant or refractory infections after hematopoietic cell transplantation
inferred← citeshttps://doi.org/10.1016/j.jtct.2021.10.005openalex-snapshot
Driving Out Chronic Lymphocytic Leukemia With CAR T Cells
inferred← citeshttps://doi.org/10.1016/j.jtct.2026.06.015openalex-snapshot
Polyomavirus-Specific T Cells in Progressive Multifocal Leukoencephalopathy: A Multicenter Retrospective Analysis
inferred← citeshttps://doi.org/10.1016/j.molmed.2020.09.005openalex-snapshot
Joining Forces: Improving Clinical Response to Cellular Immunotherapies with Small-Molecule Inhibitors
inferred← citeshttps://doi.org/10.1016/j.omtm.2017.02.001openalex-snapshot
Toward a Rapid Production of Multivirus-Specific T Cells Targeting BKV, Adenovirus, CMV, and EBV from Umbilical Cord Blood
inferred← citeshttps://doi.org/10.1016/j.omtm.2018.12.010openalex-snapshot
In Vitro Expansion of Anti-viral T Cells from Cord Blood by Accelerated Co-cultured Dendritic Cells
inferred← citeshttps://doi.org/10.1016/j.omtm.2020.08.015openalex-snapshot
Engineered Antigen-Specific T Cells Secreting Broadly Neutralizing Antibodies: Combining Innate and Adaptive Immune Response against HIV
inferred← citeshttps://doi.org/10.1016/j.omtm.2020.09.011openalex-snapshot
Regeneration of Tumor-Antigen-Specific Cytotoxic T Lymphocytes from iPSCs Transduced with Exogenous TCR Genes
inferred← citeshttps://doi.org/10.1016/j.omtm.2022.02.012openalex-snapshot
Tacrolimus-resistant SARS-CoV-2-specific T cell products to prevent and treat severe COVID-19 in immunosuppressed patients
inferred← citeshttps://doi.org/10.1016/j.omton.2024.200814openalex-snapshot
Rejection resistant CD30.CAR-modified Epstein-Barr virus-specific T cells as an off-the-shelf platform for CD30+ lymphoma
inferred← citeshttps://doi.org/10.1016/j.physbeh.2018.04.035openalex-snapshot
A single exercise bout augments adenovirus-specific T-cell mobilization and function
inferred← citeshttps://doi.org/10.1016/j.semarthrit.2024.152396openalex-snapshot
Qualitative evaluation of connective tissue disease with cytomegalovirus infection: A meta-analysis of case reports
inferred← citeshttps://doi.org/10.1016/j.trim.2022.101539openalex-snapshot
Cytomegalovirus and other herpesviruses after hematopoietic cell and solid organ transplantation: From antiviral drugs to virus-specific T cells
inferred← citeshttps://doi.org/10.1016/j.xcrm.2022.100697openalex-snapshot
Resolving SARS-CoV-2 CD4+ T cell specificity via reverse epitope discovery
inferred← citeshttps://doi.org/10.1016/j.xcrm.2023.101327openalex-snapshot
iPSC-derived hypoimmunogenic tissue resident memory T cells mediate robust anti-tumor activity against cervical cancer
inferred← citeshttps://doi.org/10.1016/j.ymthe.2021.05.021openalex-snapshot
Protective T cell receptor identification for orthotopic reprogramming of immunity in refractory virus infections
inferred← citeshttps://doi.org/10.1016/j.ymthe.2024.11.035openalex-snapshot
Managing allorejection in off-the-shelf CAR-engineered cell therapies
inferred← citeshttps://doi.org/10.1038/bmt.2017.232openalex-snapshot
Viral-specific T-cell transfer from HSCT donor for the treatment of viral infections or diseases after HSCT
inferred← citeshttps://doi.org/10.1038/s41409-019-0614-1openalex-snapshot
Therapeutic advantages provided by banked virus-specific T-cells of defined HLA-restriction
inferred← citeshttps://doi.org/10.1038/s41423-021-00829-yopenalex-snapshot
Comparable anti-CMV responses of transplant donor and third-party CMV-specific T cells for treatment of CMV infection after allogeneic stem cell transplantation
inferred← citeshttps://doi.org/10.1038/s41573-019-0051-2openalex-snapshot
‘Off-the-shelf’ allogeneic CAR T cells: development and challenges
inferred← citeshttps://doi.org/10.1038/s41573-023-00807-1openalex-snapshot
Mechanisms of resistance to chimeric antigen receptor-T cells in haematological malignancies
inferred← citeshttps://doi.org/10.1038/s41591-023-02480-8openalex-snapshot
SARS-CoV-2-specific T cell therapy for severe COVID-19: a randomized phase 1/2 trial
inferred← citeshttps://doi.org/10.1038/s41598-018-36055-2openalex-snapshot
A gB/CD3 bispecific BiTE antibody construct for targeting Human Cytomegalovirus-infected cells
inferred← citeshttps://doi.org/10.1053/j.seminhematol.2019.03.003openalex-snapshot
Veto cells for safer nonmyeloablative haploidentical HSCT and CAR T cell therapy
inferred← citeshttps://doi.org/10.1053/j.sempedsurg.2017.07.002openalex-snapshot
Post-transplant lymphoproliferative disorder after solid-organ transplant in children
inferred← citeshttps://doi.org/10.1055/s-0042-116550openalex-snapshot
Third-Party-T-Zell-Spender: eine alternative Quelle virusspezifischer T-Zellen für die adoptive Immuntherapie
inferred← citeshttps://doi.org/10.1080/14712598.2021.1857720openalex-snapshot
Cell therapy for cytomegalovirus infection
inferred← citeshttps://doi.org/10.1093/cid/ciab371openalex-snapshot
Vaccinated and Convalescent Donor–Derived Severe Acute Respiratory Syndrome Coronavirus 2–Specific T Cells as Adoptive Immunotherapy for High-Risk Coronavirus Disease 2019 Patients
inferred← citeshttps://doi.org/10.1093/cid/ciad233openalex-snapshot
Therapy With Allogeneic Severe Acute Respiratory Syndrome Coronavirus-2–Specific T Cells for Persistent Coronavirus Disease 2019 in Immunocompromised Patients
inferred← citeshttps://doi.org/10.1093/femsre/fuz008openalex-snapshot
Drug development against human adenoviruses and its advancement by Syrian hamster models
inferred← citeshttps://doi.org/10.1093/infdis/jiac500openalex-snapshot
Manufacture and Characterization of Good Manufacturing Practice-Compliant SARS-COV-2 Cytotoxic T Lymphocytes
inferred← citeshttps://doi.org/10.1097/cco.0000000000000481openalex-snapshot
T lymphocytes as therapeutic arsenal for patients with hematological malignancies
inferred← citeshttps://doi.org/10.1097/cji.0000000000000197openalex-snapshot
Early Experience With CliniMACS Prodigy CCS (IFN-gamma) System in Selection of Virus-specific T Cells From Third-party Donors for Pediatric Patients With Severe Viral Infections After Hematopoietic Stem Cell Transplantation
inferred← citeshttps://doi.org/10.1097/moh.0000000000000461openalex-snapshot
Restoring antiviral immunity with adoptive transfer of ex-vivo generated T cells
inferred← citeshttps://doi.org/10.1097/mop.0000000000000445openalex-snapshot
Management of post-transplant lymphoproliferative disorders
inferred← citeshttps://doi.org/10.1097/qco.0000000000000375openalex-snapshot
Cytomegalovirus disease in hematopoietic stem cell transplant patients: current and future therapeutic options
inferred← citeshttps://doi.org/10.1097/qco.0000000000000787openalex-snapshot
Epstein–Barr virus posttransplant lymphoproliferative disorder: update on management and outcomes
inferred← citeshttps://doi.org/10.1097/tp.0000000000002776openalex-snapshot
The Identity Card of T Cells—Clinical Utility of T-cell Receptor Repertoire Analysis in Transplantation
inferred← citeshttps://doi.org/10.1097/tp.0000000000005380openalex-snapshot
Standardizing Care and Management of Cytomegalovirus Infections in Solid Organ Transplant Recipients: Highlights From the Fourth Consensus Guidelines
inferred← citeshttps://doi.org/10.1101/2022.06.26.497669openalex-snapshot
Antiviral T-cell Biofactory platform for SARS-CoV-2
inferred← citeshttps://doi.org/10.1111/ajt.16547openalex-snapshot
Distinct immunopathological mechanisms of EBV-positive and EBV-negative posttransplant lymphoproliferative disorders
inferred← citeshttps://doi.org/10.1111/bjh.16052openalex-snapshot
Toward the understanding of a successful virus‐specific T‐cell therapy: T‐cell receptor sequencing demonstrates persistence of virus‐specific T cells after antiviral immunotherapy
inferred← citeshttps://doi.org/10.1111/bjh.16053openalex-snapshot
T‐cell receptor sequencing demonstrates persistence of virus‐specific T cells after antiviral immunotherapy
inferred← citeshttps://doi.org/10.1111/bjh.70136openalex-snapshot
Adoptive transfer of third‐party donor CMV ‐specific T cells for refractory cytomegalovirus infection following umbilical cord blood transplantation
inferred← citeshttps://doi.org/10.1111/tan.15419openalex-snapshot
Development and characterization of a cell donor registry for virus‐specific T cell manufacture in a blood bank
inferred← citeshttps://doi.org/10.1111/tid.13602openalex-snapshot
Adoptive transfer of ex vivo expanded SARS‐CoV‐2‐specific cytotoxic lymphocytes: A viable strategy for COVID‐19 immunosuppressed patients?
inferred← citeshttps://doi.org/10.1111/tid.14157openalex-snapshot
Infections after chimeric antigen receptor (CAR)‐T‐cell therapy for hematologic malignancies
inferred← citeshttps://doi.org/10.1111/trf.15186openalex-snapshot
Evaluation of peripheral blood mononuclear cell collection by leukapheresis
inferred← citeshttps://doi.org/10.1126/scitranslmed.aap9630openalex-snapshot
Hematopoietic stem cell transplantation in its 60s: A platform for cellular therapies
inferred← citeshttps://doi.org/10.1128/jvi.01705-17openalex-snapshot
Dynamics of Sendai Virus Spread, Clearance, and Immunotherapeutic Efficacy after Hematopoietic Cell Transplant Imaged Noninvasively in Mice
inferred← citeshttps://doi.org/10.1134/s0006297916110146openalex-snapshot
Recombinant MHC tetramers for isolation of virus-specific CD8+ cells from healthy donors: Potential approach for cell therapy of posttransplant cytomegalovirus infection
inferred← citeshttps://doi.org/10.1136/jitc-2020-001608openalex-snapshot
'Off-the-shelf’ allogeneic antigen-specific adoptive T-cell therapy for the treatment of multiple EBV-associated malignancies
inferred← citeshttps://doi.org/10.1146/annurev-cancerbio-050216-034351openalex-snapshot
Chimeric Antigen Receptors: A Paradigm Shift in Immunotherapy
inferred← citeshttps://doi.org/10.1155/2017/6401086openalex-snapshot
Posttransplant Lymphoproliferative Disease Presenting as an Extracranial Mass
inferred← citeshttps://doi.org/10.1159/000484051openalex-snapshot
Specific Adoptive Cellular Immunotherapy in Allogeneic Stem Cell Transplantation
inferred← citeshttps://doi.org/10.1172/jci138649openalex-snapshot
Autologous CMV-specific T cells are a safe adjuvant immunotherapy for primary glioblastoma multiforme
inferred← citeshttps://doi.org/10.1172/jci165476openalex-snapshot
Third-party cytomegalovirus-specific T cells improved survival in refractory cytomegalovirus viremia after hematopoietic transplant
inferred← citeshttps://doi.org/10.1182/blood.2019000924openalex-snapshot
Virus-specific T-cell therapies for patients with primary immune deficiency
inferred← citeshttps://doi.org/10.1182/blood.2020008488openalex-snapshot
SARS-CoV-2–specific T cells are rapidly expanded for therapeutic use and target conserved regions of the membrane protein
inferred← citeshttps://doi.org/10.1182/blood.2021012249openalex-snapshot
Cellular therapies for the treatment and prevention of SARS-CoV-2 infection
inferred← citeshttps://doi.org/10.1182/bloodadvances.2020002735openalex-snapshot
Adoptive therapy with CMV-specific cytotoxic T lymphocytes depends on baseline CD4+ immunity to mediate durable responses
inferred← citeshttps://doi.org/10.1182/bloodadvances.2020003073openalex-snapshot
Virus-specific T-cell therapy to treat BK polyomavirus infection in bone marrow and solid organ transplant recipients.
inferred← citeshttps://doi.org/10.1182/bloodadvances.2023011496openalex-snapshot
HLA reduction of human T cells facilitates generation of immunologically multicompatible cellular products
inferred← citeshttps://doi.org/10.1186/s10020-025-01420-1openalex-snapshot
CD4 T-cell platform for delivering interferons as an antiviral countermeasure with a focus on SARS-CoV-2
inferred← citeshttps://doi.org/10.1186/s12865-022-00497-1openalex-snapshot
In Vitro Generation of BK polyomavirus-specific T cells for adoptive cell therapy in refractory cystitis hemorrhagic patients after hematopoietic stem cell transplantation
inferred← citeshttps://doi.org/10.1186/s12967-019-1988-yopenalex-snapshot
A strategy to protect off-the-shelf cell therapy products using virus-specific T-cells engineered to eliminate alloreactive T-cells
inferred← citeshttps://doi.org/10.1186/s12967-020-02301-3openalex-snapshot
High-intensity interval training in allogeneic adoptive T-cell immunotherapy – a big HIT?
inferred← citeshttps://doi.org/10.1186/s13045-025-01737-8openalex-snapshot
Recent advances in universal chimeric antigen receptor T cell therapy
inferred← citeshttps://doi.org/10.1186/s40425-017-0239-0openalex-snapshot
The why, what, and how of the new FACT standards for immune effector cells
inferred← citeshttps://doi.org/10.1371/journal.pone.0224211openalex-snapshot
Skewed T cell responses to Epstein-Barr virus in long-term asymptomatic kidney transplant recipients
inferred← citeshttps://doi.org/10.1371/journal.pone.0252666openalex-snapshot
Microfluidics sorting enables the isolation of an intact cellular pair complex of CD8+ T cells and antigen-presenting cells in a cognate antigen recognition-dependent manner
inferred← citeshttps://doi.org/10.1371/journal.ppat.1010339openalex-snapshot
SARS-CoV-2-specific T cells generated for adoptive immunotherapy are capable of recognizing multiple SARS-CoV-2 variants
inferred← citeshttps://doi.org/10.18632/oncotarget.23531openalex-snapshot
Personalized adoptive immunotherapy for patients with EBV-associated tumors and complications: Evaluation of novel naturally processed and presented EBV-derived T-cell epitopes
inferred← citeshttps://doi.org/10.21037/sci.2017.05.03openalex-snapshot
Reconstitution of adaptive immunity after umbilical cord blood transplantation: impact on infectious complications
inferred← citeshttps://doi.org/10.23880/pdraj-16000107openalex-snapshot
Adoptive CD8+ T-cell Therapy Possibilities
inferred← citeshttps://doi.org/10.24875/sangre.m24000036openalex-snapshot
Generación de un registro de donantes de linfocitos: experiencia del REDOCEL
inferred← citeshttps://doi.org/10.26800/lv-143-supl2-3openalex-snapshot
Simpozij 1 – Dobrovoljno davalaštvo i uzimanje krvi
inferred← citeshttps://doi.org/10.29245/2578-3009/2018/3.1145openalex-snapshot
Clinical implications of Epstein-Barr virus strain diversity
inferred← citeshttps://doi.org/10.2991/chi.d.190613.001openalex-snapshot
Allogeneic Stem Cell Transplantation with CD34+ Cell Selection
inferred← citeshttps://doi.org/10.3389/fcimb.2022.1027341openalex-snapshot
Features of cytomegalovirus infection and evaluation of cytomegalovirus-specific T cells therapy in children’s patients following allogeneic hematopoietic stem cell transplantation: A retrospective single-center study
inferred← citeshttps://doi.org/10.3389/fimmu.2016.00500openalex-snapshot
Recent Developments in Cellular Immunotherapy for HSCT-Associated Complications
inferred← citeshttps://doi.org/10.3389/fimmu.2017.01591openalex-snapshot
Comprehensive Analysis of Cytomegalovirus pp65 Antigen-Specific CD8+ T Cell Responses According to Human Leukocyte Antigen Class I Allotypes and Intraindividual Dominance
inferred← citeshttps://doi.org/10.3389/fimmu.2018.00153openalex-snapshot
Current Status of Gene Engineering Cell Therapeutics
inferred← citeshttps://doi.org/10.3389/fimmu.2019.00621openalex-snapshot
Mycobacteria-Specific T Cells May Be Expanded From Healthy Donors and Are Near Absent in Primary Immunodeficiency Disorders
inferred← citeshttps://doi.org/10.3389/fimmu.2020.01694openalex-snapshot
Cellular Therapeutic Approaches to Cytomegalovirus Infection Following Allogeneic Stem Cell Transplantation
inferred← citeshttps://doi.org/10.3389/fimmu.2020.586168openalex-snapshot
HLA Class I Knockout Converts Allogeneic Primary NK Cells Into Suitable Effectors for “Off-the-Shelf” Immunotherapy
inferred← citeshttps://doi.org/10.3389/fimmu.2020.618427openalex-snapshot
Allogeneic CAR Cell Therapy—More Than a Pipe Dream
inferred← citeshttps://doi.org/10.3389/fimmu.2021.640082openalex-snapshot
Allogeneic CAR T Cells: An Alternative to Overcome Challenges of CAR T Cell Therapy in Glioblastoma
inferred← citeshttps://doi.org/10.3389/fimmu.2021.703256openalex-snapshot
Cytomegalovirus in Haematological Tumours
inferred← citeshttps://doi.org/10.3389/fimmu.2021.751869openalex-snapshot
Off-the-Shelf Partial HLA Matching SARS-CoV-2 Antigen Specific T Cell Therapy: A New Possibility for COVID-19 Treatment
inferred← citeshttps://doi.org/10.3389/fimmu.2021.796379openalex-snapshot
Immunoinformatic Analysis Reveals Antigenic Heterogeneity of Epstein-Barr Virus Is Immune-Driven
inferred← citeshttps://doi.org/10.3389/fimmu.2023.1069749openalex-snapshot
Trans-population graph-based coverage optimization of allogeneic cellular therapy
inferred← citeshttps://doi.org/10.3389/fimmu.2023.1237782openalex-snapshot
The two-step approach to allogeneic hematopoietic stem cell transplantation
inferred← citeshttps://doi.org/10.3390/cancers12020328openalex-snapshot
Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disorders after Hematopoietic Stem Cell Transplantation: Pathogenesis, Risk Factors and Clinical Outcomes
inferred← citeshttps://doi.org/10.3390/cancers13040598openalex-snapshot
T-Cell Dysfunction as a Limitation of Adoptive Immunotherapy: Current Concepts and Mitigation Strategies
inferred← citeshttps://doi.org/10.3390/cancers14092266openalex-snapshot
Engineering Induced Pluripotent Stem Cells for Cancer Immunotherapy
inferred← citeshttps://doi.org/10.3390/cells10112845openalex-snapshot
From Hematopoietic Stem Cell Transplantation to Chimeric Antigen Receptor Therapy: Advances, Limitations and Future Perspectives
inferred← citeshttps://doi.org/10.3390/cells13020146openalex-snapshot
Allogeneic CAR-T Therapy Technologies: Has the Promise Been Met?
inferred← citeshttps://doi.org/10.3390/cells7100155openalex-snapshot
Allogeneic CAR-T Cells: More than Ease of Access?
inferred← citeshttps://doi.org/10.3390/ijms232315122openalex-snapshot
Antigen-Specific T Cells and SARS-CoV-2 Infection: Current Approaches and Future Possibilities
inferred← citeshttps://doi.org/10.3390/pharmaceutics16101321openalex-snapshot
Use of Specific T Lymphocytes in Treating Cytomegalovirus Infection in Hematopoietic Cell Transplant Recipients: A Systematic Review
inferred← citeshttps://doi.org/10.3390/v16121884openalex-snapshot
Antiviral Stewardship in Transplantation
inferred← citeshttps://doi.org/10.3390/v17050599openalex-snapshot
Treating Adenovirus Infection in Transplant Populations: Therapeutic Options Beyond Cidofovir?
inferred← citeshttps://doi.org/10.3410/f.729972437.793569260openalex-snapshot
Faculty Opinions recommendation of Toward a Rapid Production of Multivirus-Specific T Cells Targeting BKV, Adenovirus, CMV, and EBV from Umbilical Cord Blood.
inferred← citeshttps://doi.org/10.3851/imp3238openalex-snapshot
Antiviral Combination Therapy for Cytomegalovirus Infection in High-Risk Infants
inferred← citeshttps://doi.org/10.5772/intechopen.112657openalex-snapshot
Immune Cell Generation from Human-Induced Pluripotent Stem Cells: Current Status and Challenges
inferred← citeshttps://doi.org/10.5772/intechopen.91954openalex-snapshot
Immunosuppression and Viral Infections
inferred← citeshttps://doi.org/10.6002/ect.2017.0354openalex-snapshot
BK Polyomavirus Immune Response With Stress on BK-Specific T Cells.
inferred← citeshttps://doi.org/10.6004/jnccn.2018.0073openalex-snapshot
Chimeric Antigen Receptor T-Cell Therapy
inferred← citeshttps://doi.org/10.6084/m9.figshare.12062103openalex-snapshot
Additional file 1 of High-intensity interval training in allogeneic adoptive T-cell immunotherapy – a big HIT?
inferred← citeshttps://doi.org/10.6084/m9.figshare.12062112openalex-snapshot
Additional file 2 of High-intensity interval training in allogeneic adoptive T-cell immunotherapy – a big HIT?
inferred← citeshttps://doi.org/10.6084/m9.figshare.12062121openalex-snapshot
Additional file 3 of High-intensity interval training in allogeneic adoptive T-cell immunotherapy – a big HIT?
inferred← citeshttps://doi.org/10.6084/m9.figshare.12062127openalex-snapshot
Additional file 4 of High-intensity interval training in allogeneic adoptive T-cell immunotherapy – a big HIT?
inferred← citeshttps://doi.org/10.6084/m9.figshare.12062136openalex-snapshot
Additional file 5 of High-intensity interval training in allogeneic adoptive T-cell immunotherapy – a big HIT?
inferred← citeshttps://doi.org/10.6084/m9.figshare.12062154openalex-snapshot
Additional file 6 of High-intensity interval training in allogeneic adoptive T-cell immunotherapy – a big HIT?
inferred← citeshttps://doi.org/10.6084/m9.figshare.12062166openalex-snapshot
Additional file 7 of High-intensity interval training in allogeneic adoptive T-cell immunotherapy – a big HIT?
inferred← citeshttps://doi.org/10.70675/265bed18z49e3z4231z9d13zffce852d9e1dopenalex-snapshot
Improving Allogeneic CAR-T cells : HLA class I KO Virus Specific T cells to limit GvHD and graft rejection
inferred← citeshttps://doi.org/10.70675/38a95b3ez3257z4048z839dza6c8786f40a2openalex-snapshot
Caractérisation immunologique et recherche de biomarqueurs innovants des lymphoproliférations post-transplantation
inferred← citeshttps://doi.org/10.70675/580ab96fzaff1z4acfz8156z822dc6e5f3d7openalex-snapshot
Defining the differential contributions of CD4+ and CD8+ T cells to CAR T cell therapy against B cell malignancies
inferred← citeshttps://doi.org/10.70675/9297b9f7z64fdz45e2z9d6fzd046830c540copenalex-snapshot
Cibles thérapeutiques des infections à adénovirus humains
inferred← citeshttps://doi.org/10.7883/yoken.jjid.2017.500openalex-snapshot
Characterization of In Vitro Expanded Virus-Specific T cells for Adoptive Immunotherapy against Virus Infection
Editorial review for independent work. ICSAC — the Institute for Complexity
Science and Advanced Computing — runs a structured editorial panel for researchers
publishing outside journals, and publishes on CiteStamp rails. Submission is free
and goes through ORCID: icsacinstitute.org/submit.